07 April 2022
Endava Announces Partnership with SOPHiA GENETICS
Endava is leveraging its technical capabilities to support SOPHiA GENETICS in its mission to inform the best course of action for patients and research worldwide by democratizing data-driven medicine.
– a Swiss healthtech company listed on Nasdaq – have engaged Endava to support them in various IT projects across software engineering, technology operations and data services. We are proud to have the opportunity to join their journey as their chosen technology provider in these areas and help them create a positive impact on patients’ care globally.
“Where others see data, we see answers” – SOPHiA GENETICS’ motto that fits their global data-sharing network that enables healthcare institutions to get quick, robust insights from their data. Powered by artificial intelligence, their SOPHiA DDM platform provides analysis and insights across multiple disease areas, from oncology to inherited disorders, where combining genomic and phenotypic information is vital to support discoveries, treatment decisions, and drug development efforts.
Marching forward on their journey to democratize data-driven medicine, SOPHiA GENETICS has rolled out an ambitious business and technology roadmap to enable dynamic growth and unleash their full potential. Bringing in the expertise of a trusted tech provider and outsourcing tech capabilities now opens a door for an integrated way to achieve further growth – this way expanding their impact and helping even more people all around the world.
With its extensive experience in healthtech, and heritage in creating flexible, scalable, secure, and well-engineered technology estates, Endava is both committed and well-prepared to support SOPHiA GENETICS on the road that they have mapped, in achieving their ambitious growth plans.
“I am personally grateful for the open, efficient, and flexible attitude Endava has demonstrated to help us arrive at this stage. I believe that we can build a lasting and meaningful partnership together.
” – VP of Engineering, Richard Warnett, SOPHiA GENETICS
Endava will support SOPHiA GENETICS with a variety of high-priority initiatives across a wide range of capabilities in the areas of software engineering, technology operations and data services.
“We are delighted to support SOPHiA GENETICS on their journey to democratize data-driven medicine. Given the clear alignment of the mission to improve patient care, focus on quality and innovation, as well as cultural fit, this is an exciting partnership for us at Endava, and we trust we will successfully contribute to the delivery of SOPHiA GENETICS product roadmap and change initiatives.
” – Isabela Buhai, Delivery Partner, Healthcare & Technology, Endava
It is excellent to be able to support such value-driven organizations like SOPHiA GENETICS, and we are looking forward to helping even more healthcare companies in the DACH region with first-in-class technology solutions.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a health care technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM
, or connect on Twitter
. Where others see data, we see answers.
Endava is reimagining the relationship between people and technology. By leveraging next-generation technologies, Endava’s agile, multi-disciplinary teams provide a combination of Product & Technology Strategies, Intelligent Experiences, and World-Class Engineering to help our clients become more engaging, responsive, and efficient.
Endava has 10,000 employees, as of December 2021, located in close-to-client locations in Western Europe, the United Kingdom, the United States, Australia, and Singapore and nearshore delivery centres in Central Europe and Latin America.
Cautionary notices from SOPHiA GENETICS
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact firstname.lastname@example.org to obtain the appropriate product information for your country of residence.
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.